Graves LM - Search Results

1

Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.

Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, Hammond SM, Graves LM. Zimmerman EI, et al. Among authors: graves lm. Mol Pharmacol. 2010 Nov;78(5):811-7. doi: 10.1124/mol.110.066258. Epub 2010 Aug 6. Mol Pharmacol. 2010. PMID: 20693279 Free PMC article.

2

Caspase-dependent cleavage of carbamoyl phosphate synthetase II during apoptosis.

Huang M, Kozlowski P, Collins M, Wang Y, Haystead TA, Graves LM. Huang M, et al. Among authors: graves lm. Mol Pharmacol. 2002 Mar;61(3):569-77. doi: 10.1124/mol.61.3.569. Mol Pharmacol. 2002. PMID: 11854437

3

A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools.

Huang M, Wang Y, Collins M, Mitchell BS, Graves LM. Huang M, et al. Among authors: graves lm. Mol Pharmacol. 2002 Sep;62(3):463-72. doi: 10.1124/mol.62.3.463. Mol Pharmacol. 2002. PMID: 12181422

4

p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression.

Wu W, Silbajoris RA, Whang YE, Graves LM, Bromberg PA, Samet JM. Wu W, et al. Among authors: graves lm. Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L883-9. doi: 10.1152/ajplung.00197.2005. Epub 2005 Jun 24. Am J Physiol Lung Cell Mol Physiol. 2005. PMID: 15980035 Free article.

5

Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.

Gardner OS, Dewar BJ, Graves LM. Gardner OS, et al. Among authors: graves lm. Mol Pharmacol. 2005 Oct;68(4):933-41. doi: 10.1124/mol.105.012260. Epub 2005 Jul 14. Mol Pharmacol. 2005. PMID: 16020742 Review.

6

Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones.

Dewar BJ, Gardner OS, Chen CS, Earp HS, Samet JM, Graves LM. Dewar BJ, et al. Among authors: graves lm. Mol Pharmacol. 2007 Nov;72(5):1146-56. doi: 10.1124/mol.107.037549. Epub 2007 Aug 8. Mol Pharmacol. 2007. PMID: 17686966

7

Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.

Leisewitz AV, Zimmerman EI, Jones SZ, Yang J, Graves LM. Leisewitz AV, et al. Among authors: graves lm. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):779-86. doi: 10.1080/15257770802145892. Nucleosides Nucleotides Nucleic Acids. 2008. PMID: 18600540 Free PMC article.

8

Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells.

Zimmerman EI, Huang M, Leisewitz AV, Wang Y, Yang J, Graves LM. Zimmerman EI, et al. Among authors: graves lm. FEBS Lett. 2009 Jan 22;583(2):425-9. doi: 10.1016/j.febslet.2008.12.041. Epub 2008 Dec 29. FEBS Lett. 2009. PMID: 19116148 Free PMC article.

9

Regulation of the Rho family small GTPase Wrch-1/RhoU by C-terminal tyrosine phosphorylation requires Src.

Alan JK, Berzat AC, Dewar BJ, Graves LM, Cox AD. Alan JK, et al. Among authors: graves lm. Mol Cell Biol. 2010 Sep;30(17):4324-38. doi: 10.1128/MCB.01646-09. Epub 2010 Jun 14. Mol Cell Biol. 2010. PMID: 20547754 Free PMC article.

10

Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.

Wang Q, Zimmerman EI, Toutchkine A, Martin TD, Graves LM, Lawrence DS. Wang Q, et al. Among authors: graves lm. ACS Chem Biol. 2010 Sep 17;5(9):887-95. doi: 10.1021/cb100099h. ACS Chem Biol. 2010. PMID: 20583816 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208 results

Search Page

Filters